JP2021184731A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021184731A5 JP2021184731A5 JP2021128846A JP2021128846A JP2021184731A5 JP 2021184731 A5 JP2021184731 A5 JP 2021184731A5 JP 2021128846 A JP2021128846 A JP 2021128846A JP 2021128846 A JP2021128846 A JP 2021128846A JP 2021184731 A5 JP2021184731 A5 JP 2021184731A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- antibody
- binding
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462010117P | 2014-06-10 | 2014-06-10 | |
| US62/010,117 | 2014-06-10 | ||
| EP15305078.6 | 2015-01-23 | ||
| EP15305078.6A EP2955196A1 (en) | 2014-06-10 | 2015-01-23 | Antibodies directed against CD127 |
| JP2017517406A JP7324565B2 (ja) | 2014-06-10 | 2015-06-10 | Ｃｄ１２７に対する抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517406A Division JP7324565B2 (ja) | 2014-06-10 | 2015-06-10 | Ｃｄ１２７に対する抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021184731A JP2021184731A (ja) | 2021-12-09 |
| JP2021184731A5 true JP2021184731A5 (OSRAM) | 2022-03-03 |
Family
ID=52434718
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517406A Active JP7324565B2 (ja) | 2014-06-10 | 2015-06-10 | Ｃｄ１２７に対する抗体 |
| JP2021128846A Pending JP2021184731A (ja) | 2014-06-10 | 2021-08-05 | Ｃｄ１２７に対する抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517406A Active JP7324565B2 (ja) | 2014-06-10 | 2015-06-10 | Ｃｄ１２７に対する抗体 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10428152B2 (OSRAM) |
| EP (2) | EP2955196A1 (OSRAM) |
| JP (2) | JP7324565B2 (OSRAM) |
| KR (1) | KR102612930B1 (OSRAM) |
| CN (1) | CN106715471B (OSRAM) |
| AP (1) | AP2016009599A0 (OSRAM) |
| AU (1) | AU2015273532C1 (OSRAM) |
| BR (1) | BR112016028755B1 (OSRAM) |
| CA (1) | CA2950823A1 (OSRAM) |
| CL (1) | CL2016003172A1 (OSRAM) |
| CR (1) | CR20160576A (OSRAM) |
| EA (1) | EA039303B1 (OSRAM) |
| HK (1) | HK1231487A1 (OSRAM) |
| IL (1) | IL249449B (OSRAM) |
| MA (1) | MA40202A (OSRAM) |
| MX (1) | MX376066B (OSRAM) |
| MY (1) | MY190889A (OSRAM) |
| NZ (1) | NZ726932A (OSRAM) |
| PE (1) | PE20170324A1 (OSRAM) |
| PH (1) | PH12016502445A1 (OSRAM) |
| RU (1) | RU2734076C2 (OSRAM) |
| SA (1) | SA516380455B1 (OSRAM) |
| SG (1) | SG11201610036PA (OSRAM) |
| TN (1) | TN2016000528A1 (OSRAM) |
| UA (1) | UA125366C2 (OSRAM) |
| WO (1) | WO2015189302A1 (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2865033C (en) | 2012-02-23 | 2021-11-02 | Stage Cell Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| EP2955196A1 (en) * | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| CA2981103A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| KR102789821B1 (ko) | 2015-03-31 | 2025-04-02 | 소리소 파마슈티컬스 인크. | 프로테아제-절단가능 링커를 갖는 펩티드 구조물 |
| MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
| WO2017125578A1 (en) | 2016-01-21 | 2017-07-27 | Vhsquared Limited | Polypeptides |
| WO2017149394A1 (en) | 2016-02-29 | 2017-09-08 | Ose Immunotherapeutics | Non-antagonistic antibodies directed against the alpha chain of the il7 receptor extracellular domain and use thereof in cancer treatment |
| MY190770A (en) * | 2016-12-09 | 2022-05-12 | Ose Immunotherapeutics | Antibodies and polypeptides directed against cd127 |
| US12258577B2 (en) | 2017-08-29 | 2025-03-25 | Ose Immunotherapeutics | Method effector cells using anti-CD127 antibodies for applications in cell therapy |
| CN110117325B (zh) * | 2018-03-09 | 2023-06-20 | 重庆市畜牧科学院 | 一种猪cd127多肽及其编码基因和应用 |
| CN113396162B (zh) | 2019-01-22 | 2024-08-16 | 百时美施贵宝公司 | 抗IL-7Rα亚基的抗体及其用途 |
| KR20230031981A (ko) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| US20230143091A1 (en) | 2019-06-21 | 2023-05-11 | Sorriso Pharmaceuticals, Inc. | Compositions |
| AU2020296979A1 (en) | 2019-06-21 | 2022-02-24 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| EP3986571A1 (en) | 2019-06-21 | 2022-04-27 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
| EP4142777A4 (en) * | 2020-04-27 | 2024-06-12 | Memorial Sloan-Kettering Cancer Center | CHIMERIC ANTIGEN RECEPTORS DIRECTED TO CD127 AND USE THEREOF |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| US20220389104A1 (en) | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
| US20250297324A1 (en) | 2022-05-30 | 2025-09-25 | Ose Immunotherapeutics | Biomarkers of IL7R Modulator Activity |
| CN115925955B (zh) * | 2022-12-30 | 2025-09-26 | 浙江正熙生物技术有限公司 | 一种抗cd127抗体及其制备方法和应用 |
| CN121002069A (zh) | 2023-01-06 | 2025-11-21 | 泰温治疗私人有限公司 | 抗原结合分子 |
| EP4455308A1 (en) | 2023-04-24 | 2024-10-30 | Les Laboratoires Servier | Il-7r gene signatures |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025089399A1 (ja) * | 2023-10-26 | 2025-05-01 | 国立研究開発法人国立がん研究センター | インターロイキン７受容体（ｉｌ－７ｒ）に対する抗体および当該抗体を含む抗体薬物コンジュゲート（ａｄｃ） |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025202213A1 (en) | 2024-03-26 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| CN118638236B (zh) * | 2024-07-09 | 2025-03-14 | 武汉爱博泰克生物科技有限公司 | 抗人cd127蛋白的抗体、抗体偶联物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| EP2032695B1 (en) | 2006-05-31 | 2018-08-15 | The Regents of The University of California | Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs |
| EP1930342B1 (en) | 2006-12-04 | 2012-01-25 | Institut Pasteur | OB-fold used as scaffold for engineering new specific binders |
| UY32038A (es) | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
| WO2010085643A1 (en) | 2009-01-22 | 2010-07-29 | University Of Miami | Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders |
| EP2528947A4 (en) * | 2010-01-28 | 2013-09-18 | Glaxo Group Ltd | CD127 BINDING PROTEINS |
| AR080291A1 (es) * | 2010-02-24 | 2012-03-28 | Rinat Neuroscience Corp | Anticuerpos antagonistas anti receptor de il-7 y procedimientos |
| EP2583980A1 (en) | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
| EP2955196A1 (en) * | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| WO2017149394A1 (en) | 2016-02-29 | 2017-09-08 | Ose Immunotherapeutics | Non-antagonistic antibodies directed against the alpha chain of the il7 receptor extracellular domain and use thereof in cancer treatment |
-
2015
- 2015-01-23 EP EP15305078.6A patent/EP2955196A1/en not_active Withdrawn
- 2015-06-10 WO PCT/EP2015/062993 patent/WO2015189302A1/en not_active Ceased
- 2015-06-10 RU RU2016151265A patent/RU2734076C2/ru active
- 2015-06-10 CA CA2950823A patent/CA2950823A1/en active Pending
- 2015-06-10 MX MX2016016236A patent/MX376066B/es active IP Right Grant
- 2015-06-10 EP EP15727989.4A patent/EP3155014A1/en active Pending
- 2015-06-10 AU AU2015273532A patent/AU2015273532C1/en active Active
- 2015-06-10 US US15/317,355 patent/US10428152B2/en active Active
- 2015-06-10 CN CN201580043066.1A patent/CN106715471B/zh active Active
- 2015-06-10 MY MYPI2016002094A patent/MY190889A/en unknown
- 2015-06-10 KR KR1020177000724A patent/KR102612930B1/ko active Active
- 2015-06-10 MA MA040202A patent/MA40202A/fr unknown
- 2015-06-10 CR CR20160576A patent/CR20160576A/es unknown
- 2015-06-10 HK HK17104912.8A patent/HK1231487A1/zh unknown
- 2015-06-10 PE PE2016002699A patent/PE20170324A1/es unknown
- 2015-06-10 EA EA201692460A patent/EA039303B1/ru unknown
- 2015-06-10 AP AP2016009599A patent/AP2016009599A0/en unknown
- 2015-06-10 SG SG11201610036PA patent/SG11201610036PA/en unknown
- 2015-06-10 NZ NZ726932A patent/NZ726932A/en unknown
- 2015-06-10 TN TN2016000528A patent/TN2016000528A1/en unknown
- 2015-06-10 JP JP2017517406A patent/JP7324565B2/ja active Active
- 2015-06-10 BR BR112016028755-0A patent/BR112016028755B1/pt active IP Right Grant
- 2015-06-10 UA UAA201613258A patent/UA125366C2/uk unknown
-
2016
- 2016-12-06 PH PH12016502445A patent/PH12016502445A1/en unknown
- 2016-12-07 IL IL249449A patent/IL249449B/en active IP Right Grant
- 2016-12-08 SA SA516380455A patent/SA516380455B1/ar unknown
- 2016-12-09 CL CL2016003172A patent/CL2016003172A1/es unknown
-
2019
- 2019-08-05 US US16/532,000 patent/US11440964B2/en active Active
-
2021
- 2021-08-05 JP JP2021128846A patent/JP2021184731A/ja active Pending
-
2022
- 2022-09-09 US US17/941,885 patent/US12371502B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021184731A5 (OSRAM) | ||
| KR102821932B1 (ko) | 항-ccr8 항체 및 이의 용도 | |
| JP7325936B2 (ja) | 改善された貯蔵及び投与のための、二重特異性抗体構築物を含む医薬組成物 | |
| JP2017522903A5 (OSRAM) | ||
| JP7011574B2 (ja) | Ｆｌｔ３及びｃｄ３に対する抗体構築物 | |
| JP6879998B2 (ja) | Ｃｄ７０及びｃｄ３に対する抗体構築物 | |
| JP6726168B2 (ja) | Ｃｄｈ１９およびｃｄ３に対する抗体コンストラクト | |
| JP6907124B2 (ja) | Ｃｄｈ３及びｃｄ３に対する二重特異性抗体構築物 | |
| JP6305919B2 (ja) | Ｍｃａｍアンタゴニスト及び治療の方法 | |
| RU2016151265A (ru) | Антитела, направленные на cd127 | |
| KR20240118898A (ko) | Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물 | |
| SA515360253B1 (ar) | أجسام مضادة مُميزة لألفا سينوكلين | |
| TW201708261A (zh) | Ｄｌｌ３及ｃｄ３抗體構築體 | |
| JP6105146B2 (ja) | Ｐａｎ−ＥＬＲ＋ＣＸＣケモカイン抗体 | |
| KR20160065981A (ko) | 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| CN110396129A (zh) | 人源化cd19抗原结合单链抗体及其嵌合抗原受体、免疫细胞和应用 | |
| TW201922773A (zh) | 雙特異性抗cd307e及抗bcma嵌合抗原受體之製造方法及用途 | |
| AU2014305658A1 (en) | An antibody therapy for amyloid beta disease | |
| CN117062837A (zh) | 特异性结合rankl和ngf的抗原结合分子及其医药用途 | |
| CN114805587B (zh) | Car-nk细胞及其在脏器和组织老化与纤维化治疗中的用途 | |
| US11702470B2 (en) | Use of CXCL13 binding molecules to promote peripheral nerve regeneration | |
| JP2024526154A (ja) | フィブロネクチン－インテグリン相互作用及びシグナル伝達を検出及び調節するための組成物及び方法 | |
| WO2025171411A1 (en) | Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions | |
| KR20230144870A (ko) | Mincle 억제제를 포함하는 신경병성 통증 치료용 약학 조성물 | |
| EA046884B1 (ru) | Фармацевтическая композиция, содержащая конструкции на основе биспецифического антитела, обеспечивающая улучшенное хранение и введение |